Patients' Satisfaction With The Fentanyl Pectin Nasal Spray For The Breakthrough Cancer Pain Management During Head And Neck Cancer Radiotherapy

• Main Author: Braniste, Viorica
• Format: Web Resource
• Language: English
• Published: Morressier 01.01.2017
• DOI: 10.26226/morressier.5afadd89f314ac000849aec5

Title: Patientsu2019 satisfaction with Fentanyl Pectin Nasal Spray for the breakthrough cancer pain management during the head and neck cancer radiotherapy.IntroductionThe high incidence of breakthrough cancer pain (BTcP) in head and neck (ENT) cancer patientsu2019 undergoing radiotherapy impacts negatively pain management. The pivotal clinical trials demonstrated the efficacy and safety of Fentanyl-Pectin-Nasal-Spray (FPNS) in the management of BTcP. Objectives To assess patientsu2019 satisfaction and tolerance of FPNS for the treatment of BTcP in ENT-cancer patients undergoing radiotherapy. MethodsThis is a non-interventional, prospective study. 92 adult ENT-cancer patients receiving radiotherapy and starting FPNS treatment for BTcP were included. At each visit during radiotherapy, patients completed a self-reported questionnaire concerning their satisfaction with clinical effectiveness of FPNS (primary outcome), tolerability and ease of use. Throughout the study, patients completed QoL questionnaires and safety data were collected. ResultsOverall, 73% of patients were satisfied or very-satisfied with FPNS efficacy. The causes of BTPc at enrolment (procedural pain associated with radiotherapy procedures), cancer localization and TNM score were associated with patientsu2019 satisfaction. The initial tumor size was determinant of satisfaction with FPNS. Overall, 87% evaluations of FPNS tolerance were positive. 23% of patients reported adverse events related to FPNS of mild to moderate intensity; the vertigo being the most frequent adverse event (11%). At the end of radiotherapy, 46% of patients reported an improvement in QoL. The majority of patients (84,7%) were satisfied with the ease of use of FPNS.ConclusionOur results show that the majority of patients using FNPS throughout radiotherapy were satisfied with the treatment. Overall, FNPS in combination with background opioid is effective for pain management in ENT-cancer patients undergoing radiotherapy.